Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
51
resultados
Última actualización
07/06/2025 [07:35:00]
Resumen de: US2025179489A1
An optimized method based on a dual promoter vector of the reprogramming factors combined with knock-down of the neural silencing complex RESTi to convert adult fibroblasts into induced neurons (iNs). We have also designed and cloned vector constructs of which some include all these components which allows for a one-step method to efficiently reprogram dermal fibroblasts including those obtained from elderly individuals. The single vector system can be used to obtain iNs of high yield and purity from biopsies from aged individuals with a range of familial and sporadic neurodegenerative disorders including Parkinson's, Huntington's as well as Alzheimer's disease.
Resumen de: WO2025113506A1
The present invention relates to the field of biomedicine. Provided are a marker that can be used for early diagnosis of Alzheimer's disease, and the use thereof. Specifically provided is a marker for early diagnosis of Alzheimer's disease. The marker is a Maf1 gene or the protein thereof. High expression of the Maf1 gene or the protein thereof in neuronal cells indicates that a subject is at high risk of developing Alzheimer's disease. The method provides a new diagnostic and therapeutic target for AD.
Resumen de: WO2024026413A2
Methods, systems and kits useful for the detection and diagnosis of neurodegenerative diseases including Alzheimer's Disease (AD)- and early-stage Parkinson's Disease-related pathology, and methods of preparing labeled immunocomplexes useful for detecting AD- and PD-related pathology are provided.
Resumen de: CN118388648A
The invention discloses an anti-human PD-L1 antibody based on a fully human antibody mouse or an antigen binding fragment thereof, a nucleic acid molecule for coding the antibody or the antigen binding fragment, and a preparation method and application of the antibody or the antigen binding fragment. The anti-human PD-L1 antibody or the antigen binding fragment thereof is a fully humanized sequence, has good specificity and affinity to PD-L1, and can effectively promote secretion of IL2 and IFN gamma of T cells. And the immunogenicity is lower. The invention further relates to a pharmaceutical composition containing the antibody or the antigen binding fragment thereof and application of the antibody or the antigen binding fragment thereof in preparation of drugs for preventing and/or treating PD-L1 related diseases.
Resumen de: AU2023334129A1
The invention relates to identification of an intron-retaining Tau splicing isoform as a novel Alzheimer's disease biomarker. Provided herein are polypeptides to generate binding molecules, such as antibodies specific for the Tau11i isoform, oligonucleotides and antibodies for use in methods for detecting the Tau11i isoform in a sample and methods for use in diagnosis for Alzheimer's disease.
Resumen de: CN118388648A
The invention discloses an anti-human PD-L1 antibody based on a fully human antibody mouse or an antigen binding fragment thereof, a nucleic acid molecule for coding the antibody or the antigen binding fragment, and a preparation method and application of the antibody or the antigen binding fragment. The anti-human PD-L1 antibody or the antigen binding fragment thereof is a fully humanized sequence, has good specificity and affinity to PD-L1, and can effectively promote secretion of IL2 and IFN gamma of T cells. And the immunogenicity is lower. The invention further relates to a pharmaceutical composition containing the antibody or the antigen binding fragment thereof and application of the antibody or the antigen binding fragment thereof in preparation of drugs for preventing and/or treating PD-L1 related diseases.
Resumen de: AU2023347307A1
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Resumen de: US2025172555A1
The present invention relates to a lateral flow test device capable of detecting the presence or absence of unfolded p53 in a liquid sample, such as a blood sample. Also provided are methods of using such a device for quantitative or qualitative measurement of U-p53 in a liquid sample. Detection of the presence of this analyte in the sample identifies if the subject has a risk to develop Alzheimer's Disease, and also is useful to confirm a diagnosis of Alzheimer's disease.
Resumen de: US2025170124A1
This disclosure provides compounds, pharmaceutical compositions, imaging compositions and methods useful for the diagnosis and/or treatment of neurodegenerative diseases. In particular, this disclosure provides compounds, including radiolabeled compounds, compositions, and methods useful for the diagnosis and/or treatment of neurodegenerative diseases associated with a-synuclein aggregation, such as Parkinson's disease, dementia with Lewy bodies, multiple systems atrophy or prodromal REM sleep behavior disorder.
Resumen de: US2025172549A1
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Resumen de: US2024141033A1
The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
Resumen de: WO2025102250A1
A method, system, composition and kit for diagnosis and differential diagnosis of Alzheimer's disease (AD) based on human brain hippocampus spatial transcriptomics. The present invention achieves rapid and efficient early diagnosis and differential diagnosis of AD cognitive disorder by means of one or more of CCK, Neurogranin and PMP2 carried in plasma extracellular vesicles (EVs), thereby achieving high-sensitivity and high-throughput detection of nervous system-derived EVs in peripheral blood, having the advantages of rapidness and low cost, and providing a new technical means and method for clinical application of AD cognitive disorder and large-scale screening-related accurate diagnosis work.
Resumen de: US2025163135A1
Disclosed herein are method of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.
Resumen de: US2025164471A1
The present disclosure provides a system comprising a communication interface and computer for assigning a label to the biomolecule fingerprint, wherein the label corresponds to a biological state. The present disclosure also provides a sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.
Resumen de: US2025163372A1
A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.
Resumen de: AU2023308198A1
The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of dementia in a middle-aged individual within a specified timeframe, for example 5, 10, 15 and/or 20 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of dementia within 5, 10, 15 and/or 20 years. In another aspect, methods are provided for evaluating risk of dementia within 5, 10, 15 and/or 20 years in a middle-aged individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 6.
Resumen de: AU2023371615A1
Provided herein are biomarkers present in cell-free DNA (cfDNA) for the early detection of pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD in a subject. The detection of such biomarkers in a subject may be used to inform methods of treating a subject with a therapy (e.g., a drug or biologic) for pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD. The biomarkers disclosed herein may also be used in methods to monitor the progression of pre-clinical AD, MCI, or AD.
Resumen de: WO2025099457A2
The invention relates to methods of analysing one or more protein complexes in body fluid samples using ultra-sensitive techniques such as single molecule pulldown. The methods find particular use in detecting protein complex biomarkers for the detection or diagnosis of neurodegenerative disorders. The invention also relates to novel combination biomarkers.
Resumen de: WO2025099460A1
The invention relates to calibration standards for use in a single-molecular detection methods, in particular to quantify protein complexes in a sample.
Resumen de: WO2025099458A1
The invention relates to methods of determining whether a subject has, or is at risk of developing, a neurodegenerative disorder using ultra-sensitive techniques, in particular a single-molecular array detection method.
Resumen de: KR20250064344A
본 발명은 알츠하이머병 동물 모델에서 안구 내 알츠하이머 치매 병리 물질의 침착을 평가하는 방법에 관한 것으로, 본 발명의 방법에 따르면, 알츠하이머병 동물 모델의 안구 내 병리 물질(β-아밀로이드 플라크)의 발현을 평가할 수 있는 바, 관련 용도로 유용하게 사용될 수 있다.
Resumen de: WO2025094139A1
This application is directed to detecting presence or quantity of at least two different molecules. A sensor includes a plurality of chambers, a nanowell array electrode, and a circuit board platform. The sensor separates, cleaves, filters, and detects the at least two different molecules selected from the group consisting of Aβ peptides and tau-protein from a sample in the plurality of nanowells. In some embodiments, the presence or quantity of at least three different Aβ peptides is detected, and an effective amount of a therapeutic compound is administrated to treat Alzheimer in a subject in need thereof.
Resumen de: WO2025096789A1
A method of assaying for activity of a protease enzyme corresponding to a disease in a subject includes selectively capturing an extracellular vesicle (EV) from a sample from the subject; contacting the EV after the capturing with a probe molecule, the probe molecule including a peptide, a fluorescent moiety on a first end of the peptide and a quenching moiety on a second end of the peptide to provide a Fluorescence Resonance Energy Transfer (FRET) pair separated by the peptide, the peptide containing a cleavage sequence for the protease enzyme; and measuring a fluorescence of at least the fluorescent moiety after the contacting to indicate a presence or absence of the occurrence of cleavage of the peptide by the protease enzyme.
Resumen de: WO2025097123A1
Aspects of the invention are drawn to methods for identifying or treating Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) in a subject. Further aspects of the invention are drawn to methods for screening the presence of an Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) signature.
Nº publicación: US2025147041A1 08/05/2025
Solicitante:
QUEST DIAGNOSTICS INVEST LLC [US]
Quest Diagnostics Investments LLC
Resumen de: US2025147041A1
Methods for the detection or quantitation of amyloid beta include detecting amyloid beta or fragments thereof by mass spectrometry. The methods may also include determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). Such methods may include the diagnosis or prognosis of Alzheimer's disease or dementia.
BOPI
Sede Electrónica
